myeloma drug lenalidomide promotes cereblon-dependent destruction ikaros proteins 
thalidomide-like drugs lenalidomide clinically important treatments multiple myeloma show promise b cell malignancies biochemical mechanisms underlying antitumor activity unknown thalidomide recently shown bind inhibit cereblon ubiquitin ligase cereblon loss zebrafish causes fin defects reminiscent limb defects seen children exposed thalidomide utero show lenalidomide-bound cereblon acquires ability target proteasomal degradation two specific b cell transcription factors ikaros family zinc finger proteins ikzf1 ikzf3 analysis myeloma cell lines revealed loss ikzf1 ikzf3 necessary sufficient lenalidomides therapeutic effect suggesting antitumor teratogenic activities thalidomide-like drugs dissociable 
